KR20150130389A - 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 - Google Patents

티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 Download PDF

Info

Publication number
KR20150130389A
KR20150130389A KR1020157027855A KR20157027855A KR20150130389A KR 20150130389 A KR20150130389 A KR 20150130389A KR 1020157027855 A KR1020157027855 A KR 1020157027855A KR 20157027855 A KR20157027855 A KR 20157027855A KR 20150130389 A KR20150130389 A KR 20150130389A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
group
cycloalkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157027855A
Other languages
English (en)
Korean (ko)
Inventor
졸란타 그렘벡카
토마즈 시에르픽키
드미트리 보르킨
제이 헤스
둑신 선
크시아오킨 리
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 미시간
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 미시간 filed Critical 더 리젠츠 오브 더 유니버시티 오브 미시간
Publication of KR20150130389A publication Critical patent/KR20150130389A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157027855A 2013-03-13 2014-03-10 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 Withdrawn KR20150130389A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
US61/780,099 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20150130389A true KR20150130389A (ko) 2015-11-23

Family

ID=51529943

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027855A Withdrawn KR20150130389A (ko) 2013-03-13 2014-03-10 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법

Country Status (11)

Country Link
US (4) US9505781B2 (https=)
EP (1) EP2968342B1 (https=)
JP (2) JP2016512514A (https=)
KR (1) KR20150130389A (https=)
CN (1) CN105188705A (https=)
AU (1) AU2014249233A1 (https=)
BR (1) BR112015022602A2 (https=)
CA (1) CA2904612A1 (https=)
IL (1) IL241193A0 (https=)
MX (1) MX2015011576A (https=)
WO (1) WO2014164543A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914730B2 (en) * 2012-09-28 2018-03-13 Cancer Research Technology Limited Azaquinazoline inhibitors of Atypical protein Kinase C
KR20150130389A (ko) 2013-03-13 2015-11-23 더 리젠츠 오브 더 유니버시티 오브 미시간 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EP4643952A3 (en) * 2016-01-26 2026-01-14 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
CN109152784B (zh) * 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
EP3805215A1 (en) * 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
BR112019012106A2 (pt) * 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
CN110691779B (zh) * 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CA3058448A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
KR20200101389A (ko) * 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CA3108449A1 (en) * 2018-08-08 2020-02-13 Sumitomo Dainippon Pharma Co., Ltd. Optically active bridged piperidine derivative
BR112021006273A2 (pt) 2018-10-03 2021-07-06 Agios Pharmaceuticals Inc inibidores de menin de pequenas moléculas
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
CA3128377A1 (en) * 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
CN114867726B (zh) 2019-10-28 2023-11-28 默沙东有限责任公司 Kras g12c突变体的小分子抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
MX2022012471A (es) 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
WO2022086986A1 (en) * 2020-10-21 2022-04-28 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
EP4334320A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
WO2022253167A1 (en) 2021-06-01 2022-12-08 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
CN117425659A (zh) 2021-06-03 2024-01-19 詹森药业有限公司 哒嗪或被螺环胺取代的1,2,4-三嗪
CA3220099A1 (en) 2021-06-17 2022-12-22 Wei Cai (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cance
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
KR20240131421A (ko) * 2021-12-31 2024-08-30 히트젠 주식회사 메닌 저해제 및 이의 용도
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
AU2009291783A1 (en) * 2008-09-10 2010-03-18 Alcon Research, Ltd Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
CN102574787B (zh) * 2009-07-30 2014-12-31 新加坡国立大学 具有潜在的抗癌活性的小分子异戊二烯基半胱氨酸羧基甲基转移酶抑制剂
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
KR20150130389A (ko) 2013-03-13 2015-11-23 더 리젠츠 오브 더 유니버시티 오브 미시간 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법

Also Published As

Publication number Publication date
US9505782B2 (en) 2016-11-29
JP2016512514A (ja) 2016-04-28
BR112015022602A2 (pt) 2017-07-18
US10160769B2 (en) 2018-12-25
MX2015011576A (es) 2016-05-16
EP2968342A1 (en) 2016-01-20
US9216993B2 (en) 2015-12-22
WO2014164543A1 (en) 2014-10-09
EP2968342A4 (en) 2016-07-27
US20160046647A1 (en) 2016-02-18
JP2018115214A (ja) 2018-07-26
US20170253611A1 (en) 2017-09-07
US20160137665A1 (en) 2016-05-19
CN105188705A (zh) 2015-12-23
EP2968342B1 (en) 2018-10-03
AU2014249233A1 (en) 2015-09-24
JP6670885B2 (ja) 2020-03-25
US9505781B2 (en) 2016-11-29
US20140275070A1 (en) 2014-09-18
CA2904612A1 (en) 2014-10-09
IL241193A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
KR20150130389A (ko) 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
CN113874374B (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
TWI436986B (zh) 新穎之２環性雜環化合物
CN101952259B (zh) 苯并二氮杂*化合物及药物组合物
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
JP7627966B2 (ja) Ｃｄ７３阻害剤、その製造方法と応用
TW202322796A (zh) 靶向p53突變體的化合物
JP2018024670A (ja) キナーゼ活性の阻害剤
WO2015127872A1 (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
EP2739618A1 (en) Quinazoline compounds as serine/threonine kinase inhibitors
WO2022216644A1 (en) Pyridinyl substituted oxoisoindoline compounds
KR20220054307A (ko) 암의 치료를 위한 1,2,4-옥사디아졸-5-온 유도체
CN117321051A (zh) 作为parp抑制剂的化合物
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
CN114206861A (zh) 用作ripk1抑制剂的稠环杂芳基化合物
CN121517419A (zh) 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物
CN118434417A (zh) 环状磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途
JP2024540264A (ja) ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用
CN120774901A (zh) Polθ抑制剂及其药物组合物和应用
WO2025247178A1 (zh) 一类prmt5抑制剂及其组合物和用途
TWI423974B (zh) 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
CN115515958A (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid